HAP1 can sequester a subset of TBP in cytoplasmic inclusions via specific interaction with the conserved TBPCORE
© Prigge and Schmidt; licensee BioMed Central Ltd. 2007
Received: 07 March 2007
Accepted: 14 September 2007
Published: 14 September 2007
Huntington's disease, spinal and bulbar muscular atrophy, and spinocerebellar ataxia 17 (SCA17) are caused by expansions in the polyglutamine (polyQ) repeats in Huntingtin protein (Htt), androgen receptor protein (AR), and TATA-binding protein (TBP), respectively. Htt-associated protein 1 (HAP1), a component of neuronal cytoplasmic stigmoid bodies (STBs), can sequester polyQ-expanded Htt and AR in STBs, thereby antagonizing formation of the nuclear aggregates associated with apoptotic neuron loss and disease progression.
Clones of HAP1 were isolated from unbiased two-hybrid screens for proteins that interact with TBP. Domain mapping showed that regions between amino acids 157 and 261 and between amino acids 473 and 582 of mouse HAP1 both bind specifically to the conserved C-terminal TBPCORE domain, away from the TBP N-terminal polyQ region. When fluorescently tagged versions of HAP1 or TBP were expressed independently in COS-7, 293, or Neuro-2a cells, all TBP localized to the nucleus and all HAP1 assembled into cytoplasmic stigmoid-like bodies (STLBs). When co-expressed, a portion of the TBP was assembled into the HAP1 STLBs while the remainder was localized to the nucleus. Although the TBP N terminus, including the polyQ region, was unnecessary for TBP-HAP1 interaction, in mammalian cells, removal of the TBP Qrepeat reduced the proportion of TBP that assembled into STLBs, whereas expansion of the Qrepeat had no significant affect on TBP subcellular localization.
HAP1 can sequester a subset of TBP protein away from the nucleus; extranuclear TBP sequestration is quantitatively influenced by the TBP polyQ repeat. These results suggest HAP1 could provide protection from SCA17 neuropathology.
The Huntingtin-associated protein, HAP1, was first identified as a protein that interacts with Huntingtin protein (Htt), the causative agent of Huntington's disease (HD) [1–5]. HD is a member of a family of diseases in which expanded polyglutamine (polyQ) repeat regions in an otherwise functionally diverse group of proteins results in neurodegenerative disorders [1, 3, 6]. This family includes dentatorubral-palidoluysian atrophy (DRPLA), caused by polyQ expansion in atrophin 1; [7, 8], spinal and bulbar muscular atrophy (SBMA or Kennedy's disease), caused by polyQ expansion in the androgen receptor, AR; [9–11], and spinocerebellar ataxias 1–3, 6, 7, and 17 (SCAs), caused by polyQ expansions in various proteins [1, 3].
In all of these diseases, expansion of gene sequences encoding the polyQ region of the individual protein results in the disease in later life [1, 3]. All are associated with neuronal accumulation of nuclear aggregates containing the affected protein as well as other proteins [1, 3]. Although some extranuclear protein aggregates can often also be found, the nuclear accumulations are implicated in inducing the cytopathic state that leads to apoptotic loss of neurons . In the case of HD, expansion of the polyQ repeat beyond ~36 residues causes an amino- (N-) terminal fragment (encoded by exon 1 of the htt gene) to be cleaved and to translocate to the nucleus, where it becomes incorporated into neuronal nuclear aggregates [12–14]. Nuclear HD aggregates typically contain proteasome subunits, chaperones, and ubiquitin [1, 3, 15, 16]. Aggregates also contain transcription factors, including the TATA-binding protein (TBP), cyclic AMP response element-binding protein (CBP), specificity factor 1 (SP1), p53, and others [17, 18]. One of these, TBP, is a general transcription factor that functions in initiation by all three nuclear RNA polymerases . In addition, TBP is, itself, a polyQ protein that, upon expansion of its polyQ repeat, forms intranuclear aggregates leading to the SCA17 neuropathology . Although TBP is generally a low abundance protein in normal somatic cells [21, 22], the nuclear aggregates in SCA17 accumulate to high levels , suggesting that the pathological state is associated with increased accumulation of nuclear TBP.
Although HAP1 interacts with Htt, it is unclear what role this might play in HD. Recent evidence suggests that HAP1 may protect against polyQ-expansion neuropathologies [24–27], a proposal known as the 'HAP1 protection hypothesis' . Thus, although expanded polyQ Htt is abundant throughout the brain, including in the HAP1-expressing hypothalamic and limbic regions in HD patients [25, 28, 29], these areas do not accumulate Htt aggregates and do not exhibit HD pathology . Moreover, evidence for a neuroprotective role of HAP1 in SBMA has been reported. Thus, HAP1 binds to AR and SBMA pathology is generally not seen in neurons expressing HAP1 . Importantly, whereas transfection of HEp-2 cells with polyQ-expanded AR results in apoptosis, co-transfection of HAP1 abrogates this effect .
Two HAP1 isoforms have been characterized in mice, HAP1-A, a 598 amino acid protein, and HAP1-B, a 628 amino acid protein, which both arise from the same gene . The difference between HAP1-A and HAP1-B stems from alternative splicing in the 3' region of the pre-mRNA and results in both proteins containing different C-terminal sequences beyond the 577 amino acid HAP1 common region [31–33]. It is not yet clear how HAP1-A and HAP1-B might differ functionally, although the predominant vesicle-associated subtype is HAP1-B .
Subcellular localization studies show that HAP1 is predominantly cytoplasmic . HAP1 is a component of stigmoid bodies (STBs) , which are non-membrane-bound cytoplasmic inclusions found in the hypothalamus and limbic regions of the brain . HAP1 expression induces formation of cytoplasmic inclusions resembling STBs, here termed stigmoid-like bodies (STLBs), in 293 human embryonic kidney carcinoma cells, HEp-2 human larynx carcinoma cells, and mouse neuronal NIE 115 cells [27, 36], suggesting that HAP1-A directs assembly of similar cytoplasmic inclusions in neuronal and non-neuronal cell types.
In the study presented here, unbiased yeast two-hybrid screens identified HAP1 as a protein that binds to TBP. Like the HAP1-interacting Htt and AR proteins, TBP is the causative agent of a polyQ-expansion-dependent neuropathology (see above). Moreover, like for Htt and AR proteins, we found that binding of HAP1 to TBP occurred away from the TBP polyQ region. Instead, interaction domain mapping studies showed that HAP1 binds specifically to the conserved C-terminal domain of TBP (TBPCORE). By inducing formation of green fluorescent protein-tagged HAP1 STLBs in 293, COS-7, or Neuro-2A cells, we show that cytoplasmic STLBs sequester some TBP while still allowing accumulation of substantial levels of TBP in the nucleus. These data suggest HAP1 can specifically associate with TBP to prevent nuclear localization of excess TBP while not impeding normal nuclear TBP accumulation and function.
Identification of HAP1 as a TBP interacting protein
Interaction of HAP1 with TBP domains
To determine whether HAP1 interacted with the conserved TBPCORE or the vertebrate-specific TBP N terminus, yeast were co-transformed with either TBP-N or TBP-C bait plasmids and the HAP1155–582 prey plasmid. Growth of all clones on SC-L-W verified the presence of both the bait and prey plasmids (Fig. 2A, left panel). In the presence an empty prey plasmid, TBP-FL, TBP-C, and TBP-N did not grow under the protein interaction selection conditions (Fig. 2A, sectors 4–6). Similarly, yeast that contained either the empty bait or empty prey plasmids (negative controls) did not grow on plates that selected for interaction of bait and prey proteins (Fig. 2A, sector 9, panels 2, 3). The HAP1155–582 clone interacted with the TBPCORE (Fig. 2A, sector 2, panels 2, 3), but not with TBP N (Fig. 2A, sector 3, panels 2, 3).
The interaction of HAP1 with Htt or AR has been shown to occur away from the polyQ repeat region in each protein, but to be influenced by expansion of the polyQ repeat [12, 27]. In two-component two hybrid screens, we found a strong interaction of HAP1 with either the TBPCORE alone (lacking the N-terminal polyQ region; Fig. 2A, sector 2, panels 2, 3) or with full length TBP protein in which the polyQ region had been replaced by two glycine residues (TBP-ΔQ; Fig. 2B). Thus, the TBP polyQ region showed no measurable contribution to the interaction of HAP1 with TBP in the yeast two-hybrid system.
All attempts at further truncating the TBPCORE region to define the interaction domain on TBP disrupted the TBP-HAP1 interaction (Fig. 2B, sectors 2–6), suggesting that the interaction might be dependent on the structural integrity of the entire TBPCORE region.
Interaction of TBP with HAP1 in co-transfected cells
Mapping the TBP-interaction domain on HAP1
Some HAP1 clones that encoded amino acids outside TBP interacting region 1 also interacted with TBP-C (Fig. 4, sectors 16, 25, 34, and 37) but not with TBP-N (Fig. 4, sectors 17, 26, 35, and 38). The shortest C-terminal HAP1 clone that interacted with TBP-C encoded amino acids 473–582, which suggested that a second TBP interaction domain resided between amino acids 473–582 of HAP1. This region is represented as the TBP interacting region 2 in Fig. 5. The amino acid sequences of TBP interacting domains 1 and 2 show no obvious similarity (Fig. 5, bottom), suggesting that these are each unique interacting domains rather than redundant versions of the same domain.
Intracellular co-localization of TBP and HAP1
When either red fluorescently labeled TBP, MED15, PTIP, or U2AF65 were transfected alone, each of these proteins localized exclusively to the nucleus where each exhibited distinct heterogenous distributions (Fig. 6A). Conversely, fluorescently labeled HAP1 was exclusively cytoplasmic, where it assembled into STLBs  (Fig. 6A). In cells expressing both TBP and HAP1, however, a portion of the TBP co-localized with HAP1 in cytoplasmic STLBs (Fig. 6B). We did not detect any HAP1 redistributing to the nucleus with TBP. Co-expression of HAP1 with either MED15, PTIP, or U2AF65 did not result in any redistribution of these non-TBP nuclear proteins into STLBs (Fig. 6B). These results suggest that TBP can be sequestered in cytoplasmic STLBs in vivo via specific interactions with HAP1. Importantly, not all TBP was sequestered in STLBs (Fig. 6B). This suggests the association did not disrupt normal nuclear localization and function of TBP, but rather, was selective for only a subset of TBP in the cells.
Although our two-component two-hybrid tests showed that the TBP polyQ region was not required for the TBP-HAP1 interaction (Fig. 2), the interaction of HAP1 with other polyQ proteins has been shown to be influenced by the length of polyQ repeats outside of their HAP1-binding domains [6, 12, 27, 49]. The length of the polyQ region in vertebrate TBP proteins has been shown to be highly variable both between and within species [50–52]; polyQ expansion beyond 36 residues in human TBP causes SCA17 . Therefore, we wished to test whether, in the context of a mammalian cell, we could detect quantitative differences in the amount of TBP that assembled into STLBs by altering the length of the polyQ repeat. Mutant versions of mouse TBP expression vectors were constructed that either replaced the normal 13-residue polyQ region with two glycines (TBP-ΔQ) or expanded the region nearly four-fold to contain 50 consecutive Q residues (TBP-Q50). When expressed alone, all three versions of full-length TBP (wild-type, ΔQ, and Q50) were exclusively nuclear (Figs 6A, 7B). When co-expressed with HAP1, all three full-length TBP proteins showed partial sequestration into cytoplasmic STLBs (Figs 6B, 7B).
HAP1 is a predominantly cytoplasmic protein that has been implicated in contributing to various processes [42, 53]. Since HAP1 has little similarity with other known proteins , much of what is known about its function has been discovered through identification of those proteins that interact with HAP1. Specific protein interaction sites on HAP1 have been mapped as follows (mouse HAP1-B amino acid numbering): amino acids 277–369 (HAP1277–369) binds with Htt; full-length HAP1-A binds to AR; HAP277–444 binds with dynactin P150Glued; HAP1245–371 binds with hepatocyte growth factor-regulated tyrosine kinase substrate protein; HAP11–312 binds with interRho-GEF Kalirin-7; HAP1219–519 binds to GABAA receptor; HAP1272–598 binds to IP31 receptor; and HAP1247–446 binds to NeuroD (ND) [27, 33, 42, 53–57]. Here we show that a clone encoding amino acids 155–582 of HAP1 bound to the TBPCORE domain in yeast two-hybrid screens (Fig. 2). We also show that TBP co-immunoprecipitated with HAP1 in transient cotransfection assays (Fig. 3). Further, two regions within HAP1 were shown to independently interact with TBP-C. Specifically, the domains of HAP that interacted with TBP are found between amino acids 157–261 and between amino acids 473–582 (Figs. 4 and 5).
We are aware of only one study that has shown a role of HAP1 in transcriptional regulation. In that study, HAP1, in conjunction with Htt, was shown to function as a scaffold protein that mediates the interaction of ND with mixed-lineage kinase 2 in the cytoplasm, resulting in phosphorylation of ND and its subsequent translocation to the nucleus . No evidence exists for cytoplasmic regulation of TBP activity, so we feel that it is unlikely that the TBP-HAP1 interaction might similarly regulate gene expression in HAP1-expressing cells. Rather, as detailed below, we favor a model based on the 'HAP1 protection hypothesis' , wherein HAP1 may help protect neuronal cells from TBP-mediated cytotoxicity.
Including this report, HAP1 has now been shown to bind specifically to three proteins associated with polyQ-dependent neuropathologies: Htt, AR, and TBP [4, 5, 27, 53]. In all cases, recognition and binding of these proteins by HAP1 is dependent on unique sequences outside of their polyQ regions [4, 27]. In other words, HAP1 does not recognize an expanded polyQ repeat per se, but rather, recognizes unique aspects of at least three specific proteins that have a propensity for causing polyQ-dependent neuropathology. Neruopathologies caused by Htt, AR, and TBP are associated with nuclear accumulation of protein aggregates, which are thought to induce cytopathic effects resulting in apoptotic neuron loss [1, 3, 20, 53, 58]. HAP1 is not associated with Htt aggregates in HD brains and HD neuropathology is not associated with brain regions having high HAP1 expression [5, 28, 34]. Thus, although Htt is expressed in many regions of the brain , regions that overlap with HAP1 expression are not vulnerable to neuropathology, leading to formulation of the 'HAP1 protection hypothesis' . Similarly, although both bulbar and forebrain neurons express high levels of AR, polyQ-expanded AR aggregates and neuropathology in SBMA patients are not observed in the forebrain regions, which express high levels of HAP1 and exhibit STBs, but rather, are restricted to the HAP1/STB-deficient bulbar regions [25, 27]. Overexpression of polyQ-expanded AR in HEp-2 cells induces apoptosis; however, co-overexpression of HAP1 suppresses apoptosis and, instead, causes formation of STLBs containing both proteins . Thus, HAP1 binds to polyQ-expanded AR though specific interactions with regions outside the polyQ domain, it sequesters polyQ-expanded AR in STLBs, and it protects cells from polyQ-expanded AR-induced apoptosis , strongly supporting a protective role for HAP1.
Although it is not clear whether HAP1 might also protect neurons from TBP-mediated neuropathology, it is intriguing that, despite ubiquitous expression of TBP in all cells of the body, most regions of the brain exhibiting high levels of HAP1 and abundant STBs do not exhibit neuropathology in SCA17 patients [4–6, 20, 23, 29]. One exception is in the striatum, which has both STBs  and SCA17-associated neuropathology [20, 23]. However, detailed analyses show that, whereas HAP1/STBs are found in the medium and large neurons of the striatum , SCA17 is associated with loss of the small neurons [20, 23].
In the current study, we show that HAP1 binds specifically to the TBPCORE and that HAP1 can sequester a subset of TBP into STLBs in co-transfected 293, COS-7, or Neuro-2a cells. Unlike the case for HAP binding to AR (see above), the HAP1-TBP interaction in yeast or mammalian cells did not require expansion of the polyQ region of TBP (Figs 2B, 4, 7, 8); however, removal of the polyQ region reduced assembly of TBP into STLBS (Figs 7, 8). Since the HAP1-binding domains of TBP, Htt, and AR are all disparate from the polyQ regions in each protein (see above), it is interesting that HAP1 binding by all three proteins should show polyQ-dependence. In transfected cells, HAP1/STLBs did not clear TBP from the nucleus (Fig. 6, 7, 8). Instead, they appeared to sequester a subset of TBP, while still allowing substantial TBP accumulation in the nucleus. It remains unclear whether the TBP protein that accumulated in the nucleus was equivalent to that sequestered in the STLBs (Figs 6, 7, 8). One possibility is that the polyQ region of each protein can influence the likelihood that that protein assumes a "state" that allows interaction with HAP1. For example, in the case of TBP, the subset of protein that is sequestered into HAP1 STLBs might be mis-folded, defective in nuclear localization, abnormally associated with other proteins, or otherwise defective, thus making this protein accessible for HAP1 binding. Further studies will be required to better understand the role of the TBP polyQ region in in vivo HAP1 association.
HAP1 has previously been shown to interact specifically and away from the polyQ repeat region with Htt and AR proteins, the causative agents of HD and SBMA, respectively [27, 53]. In the current study, we isolated HAP1 as a TBPCORE-interacting protein from unbiased two-hybrid screens. The interacting domains were mapped and the interactions were confirmed in co-immunoprecipitation assays. Sub-cellular co-localization studies indicated that HAP1-induced STLBs could sequester a subset of overexpressed TBP, but not other overexpressed nuclear proteins, away from the nucleus. Although the co-localization was modeled in an overexpression system, we suspect this may be a suitable model for a HAP1-TBP interaction. Thus, in normal cells, all TBP goes to the nucleus where it functions in transcription initiation and a HAP1-TBP interaction would not occur. Only in the case of a TBP expression anomaly would there be a possible physiological situation in which a HAP1-TBP interaction may be important to combat TBP-mediated cytotoxicity. In our co-localization system, the anomaly is strong overexpression of TBP in the transiently co-transfected cells; in SCA17 patients, anomalous expansion of the TBP polyQ repeat results in overaccumulation TBP, which assembles into nuclear aggregates and results in apoptotic neuronal loss . Interestingly, neurons expressing HAP1 and possessing STBs appear to be refractory to nuclear aggregate formation and SCA17 cytopathology (see above). Thus, we posit that HAP1 plays a neuroprotective role in preventing nuclear aggregate formation in the presence of anomalous TBP accumulation.
All renewable reagents generated for this study, including all plasmids, expression vectors, yeast two-hybrid libraries, and yeast strains, are available on request for unrestricted non-profit research use unless specifically regulated by other parties.
Two-hybrid baits, libraries, transformations, and screens
5'-tatgcggccgc agtcga c ttgtacagctcgtccatgcc-3'
5'-tatgtcg ac acagagggatcaagaccagca-3'
5'-tatgcggc cgc tgtctcagccttagggtgt-3'
5'-tatgcggccg c acacattccagaatgagcatc-3'
5'-tatgcggccg c ccataatcctgcatgtaggag-3'
5'-atactgcag ttgctactgc ctgttgctgctgttgctgctgctgttgctgttgctgctgttgctgttgctgctgttgttgctgctgctgttgctgctgctgctgttgttgctgctgttgctgctgttgctgctgctgttgttgctgctgctgttgctgttgctgctgctgtctttgttgctcttccaaaatagagagact-3'
linker (top strand)
linker (bottom strand)
Oligo(dT)-primed cDNA prey libraries were constructed and inserted into the pPC86 vector (Gibco BRL ProQuest) as follows. Total RNA was extracted and CsCl-purified  from embryonic day 10.5 (E10.5) wild-type C57Bl/6J whole pregnant uteri or placentas. In each case, either whole pregnant uteri or placentas were obtained from four pregnant dams to generate a pool of RNA. Poly(A+) mRNA from these samples was purified using Oligo(dT)25 Dynabeads (Dynal Biotech ASA) following the manufacturer's protocols. Oligo(dT)-primed libraries were constructed from ~3 μg of poly(A+) RNA; cDNA inserts for each library had an average size of >1 kb (Fig. 1B). The whole pregnant uteri and placental libraries contained ~2.1 × 106 and ~2.5 × 106 independent recombinants, respectively; each with ~95% bearing inserts (Fig. 1B). To access more 5' regions of prey cDNAs, a random hexamer-primed library was also constructed using 3 μg each of whole pregnant uteri and placental poly(A+) RNA. Construction of random-primed cDNAs was performed using a standard oligo(dT)-primed cDNA synthesis kit (Stratagene), with the following adaptations. First, instead of an oligo(dT) primer, random hexamer oligonucleotides were used to prime the first-strand cDNA. Second, a linker containing a 5' Eco RI overhang and a blunt 3' end was constructed by annealing the 5' and 3' linker oligos (Table 1) and ligating this to the blunt-ended double-strand cDNA product. Both the 5' and 3' ends of the cDNA had Eco RI overhangs (Table 1), which allowed direct insertion of the library product into an Eco RI-digested vector. Two versions of the random-primed library were constructed and subsequently pooled. The first consisted of non-amplified cDNA that was inserted into the Eco RI site of pPC86. This library contained ~6 × 105 primary transformants with ~60% bearing inserts. The second library was constructed from random-primed cDNA that had been amplified by PCR using primers that annealed to the linker sequences located at the 5' and 3' ends of the final cDNA library product. PCR-amplified cDNA was digested with Not I and inserted into the Not I site of pPC86. This library contained ~1.8 × 106 independent recombinants with ~90% bearing inserts. After pooling, the combined library consisted of ~2.4 × 106 cDNA clones and had an average insert size of ~1.0 kb with ~90% bearing inserts (Fig. 1B).
All interactions were tested in Saccharomyces cerevisiae strain MaV203 (Gibco BRL), which contained the HIS3, URA3, and LacZ reporters, each under the control of a different promoter. For library transformations, a culture of MaV203 that contained the TBP bait construct was grown at 30°C for 48 hours in liquid synthetic complete medium (SC) lacking leucine (SC-L) (QBIOgene). This culture was used to seed 300 ml of 2× yeast extract/peptone/adenine/dextrose (YPAD) at 5 × 106 yeast/ml, which was determined by counting on a hemacytometer. The culture was grown at 30°C for ~5 hours to a density of 2 × 107 yeast/ml. Yeast were collected by centrifugation, washed once with water and once with 100 mM LiAc, and transformed with 14.4 ml 50% PEG (average m.w. 3350), 2.16 ml 1.0 M LiAc, 0.3 ml 10 mg/ml sheared denatured salmon sperm DNA, and 120 μg of the cDNA library in pPC86. Single- or two-component transformations of bait and/or prey plasmids into yeast used a standard PEG/LiAc protocol .
Two-hybrid screens were performed on SC medium lacking leucine, tryptophan, histidine, and uracil (SC-L-W-H-U). Both two-hybrid screens used TBP-FL as bait to screen either a combination of 50% whole pregnant uteri and 50% placental (screen 1) or random-primed (screen 2) cDNA prey libraries. Primary transformants were transferred onto a new SC-L-W-H-U plate and clones that grew well on these plates were transferred to either a SC-L-W-H + 80 mM 3-AT plate or were grown on SC-L-W and tested for LacZ expression following the X-Gal Assay protocol detailed in the ProQuest Two-Hybrid system manual (Gibco BRL cat. series 10835). Prey plasmids from clones that grew under all selection conditions and scored positive for LacZ expression (turned blue) were isolated from yeast by glass bead lysis . Recovered plasmids were transformed into bacteria, clones were selected, and inserts were sequenced to determine the cDNA identity. Isolated prey plasmids were re-transformed into MaV203 with the bait or with the empty pDBLeu plasmid (auto-activation test) and grown on SC-L-W-H + 75 mM 3-AT, and SC-L-W-H-U plates to verify the interaction.
To identify the domain of TBP that interacted with HAP1, TBP bait constructs in combination with the empty pPC86 prey plasmid (auto-activation test) or with either the HAP1 random-primed or the HAP1 oligo(dT)-primed clone were co-transformed into MaV203 and plated onto SC-L-W. Individual colonies that grew on SC-L-W plates (containing both the bait and prey plasmid) were suspended in water and streaked onto SC-L-W, SC-L-W-H + 75 mM 3-AT, and SC-L-W-H-U plates to verify the interaction.
Interaction domain mapping
For generating a HAP1 deletion mutant series, a random-primed yeast two hybrid prey plasmid isolated as a TBP interactor, encoding amino acids 155–582 of the mouse HAP1-B cDNA, was used as the template for PCR amplification. PCR primer sets for amplification of each truncated clone are indicated in Table 1. PCR products were digested with Sal I and Not I and were inserted into the pPC86 prey vector.
Three plasmid clones of each truncated HAP1 construct were isolated and separately co-transformed into yeast with pDBLeu-mTBP-N, pDBLeu-mTBP-C, or empty pDBLeu bait plasmid. Yeast were plated onto SC-L-W agar plates and grown at 30°C. Resultant colonies were suspended in water and streaked onto SC-L-W, SC-L-W-H + 75 mM 3AT, and SC-L-W-H-U to test each protein interaction pair.
TBP-ΔQ and truncated TBP-C clones were co-transformed into yeast with pPC86-mHAP1-A7-598 or the empty pPC86 prey plasmid. Yeast were plated onto SC-L-W agar plates and grown at 30°C. Two resultant colonies for each yeast co-transfection were suspended in water and streaked onto SC-L-W, SC-L-W-H + 75 mM 3AT, and SC-L-W-H-U to test each protein interaction pair.
A HAP1 cDNA encoding amino acids 155–582 of the mouse HAP1-B protein was inserted into the Eco RI site of pCMV-MYC (BD Biosciences). The TBP-FL cDNA was inserted between the Sal I and Not I sites in both pCMV-HA (BD Biosciences) and pFLAG-CMV-2SN, which is a modified version of pFLAG-CMV-2 (Sigma). pFLAG-CMV-2SN contained a modified polylinker, and was constructed by inserting a linker oligonucleotide containing internal Sal I and Not I sites and a 5' Hind III and 3' Bam HI into Hind III/Bam HI-digested pFLAG-CMV-2. A green fluorescent protein- (GFP-) tagged TBP construct, pFLAG-CMV-GFP-TBP-FL, was constructed by PCR amplification of EGFP with primers GFP-N-start and GFP-C-end (Table 1). PCR-amplified EGFP was digested with Sal I and inserted into the Sal I site upstream of TBP-FL in pFLAG-CMV-2SN.
Line 293 cells were transfected and lysates were prepared as described previously . Lysates were pre-adsorbed with 10 μl of non-specific rabbit polyclonal antibody and 20 μl of Protein G plus Protein A agarose (Calbiochem) for 2 hours, rotating at 4°C, after which the agarose was pelleted and 0.5 ml of supernatant was transferred to a new tube containing 12.5 μl of either anti-TBP NC rabbit polyclonal antibody  or a non-specific control antibody and rotated at 4°C for 16 hours, followed by one hour with 30 μl of Protein G plus/Protein A agarose added. Beads were washed once with lysis buffer, four times with wash buffer (50 mM Tris-HCl, pH 7.4, 300 mM NaCl, 2% TX-100, 10% glycerol, and 1 mM PMSF), and a final time with wash buffer that contained 100 mM NaCl. Proteins bound to agarose beads were released by boiling for 5 minutes in 1× SDS-PAGE sample buffer, separated by polyacrylamide gel electrophoresis, and analyzed by Western blotting with the antibodies indicated in figure legends.
COS-7 cells at 40–50% confluence on 10 cm dishes were transfected and lysates were prepared as described previously , with the following modifications. Cells were lysed in 750 μl of lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% TX-100, 0.1% SDS, 0.5% deoxycholic acid, 10% glycerol, 1 mM EDTA, 1 mM PMSF, 5 μg/ml leupeptin-pepstatinaprotinin, and 0.1 mM Na3V04). After lysis, cells were brought to a final volume of 1.5 ml with 150 mM NaCl wash buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% TX-100, 10% glycerol, 1 mM EDTA, 1 mM PMSF, 0.5 μg/ml leupeptin-pepstatin-aprotinin, and 0.1 mM Na3V04). Lysates were pre-adsorbed with 2 μg of non-specific mouse monoclonal antibody and 20 μl of Protein G plus Protein A agarose (Calbiochem) for 2 hours, rotating at 4°C, after which the agarose was pelleted and 1.4 ml of supernatant was transferred to a new tube containing 5 μg of either anti-FLAG M2 monoclonal antibody (Sigma) or a non-specific control antibody and rotated at 4°C for 16 hours, followed by one hour with 40 μl of Protein G plus/Protein A agarose added. Beads were washed once with 150 mM NaCl wash buffer, three times with 300 mM NaCl wash buffer (50 mM Tris-HCl, pH 7.4, 300 mM NaCl, 2% TX-100, 10% glycerol, 0.5 μg/ml leupeptin-pepstatin-aprotinin, and 1 mM PMSF), and a final time with 150 mM NaCl wash buffer. Proteins bound to agarose beads were released by boiling for 5 minutes in 1× SDSPAGE sample buffer, separated by polyacrylamide gel electrophoresis, and analyzed by Western blotting with the antibodies indicated in the figure legend.
In vivo co-localization assays
For co-localization assays, a full-length cDNA of mouse TBP was PCR-amplified with TBPN-start-Bgl II and TBP-C-end primers (Table 1), and inserted between the Bgl II and Kpn I sites in the pDsRed2-C1 plasmid (BD Biosciences). TBP-ΔQ was inserted between the Sal I and Not I sites in pDsRed2-C1SN, which is a modified version of pDsRed2-C1. pDsRed2-C1SN was constructed by inserting a linker oligonucleotide containing internal Sal I and Not I sites and 5'Eco RI and 3' Bam HI overhangs into Eco RI/Bam HI-digested pDsRed2-C1. TBP-Q50 was constructed using primers TBP-N-start-Sal I and TBP-Q50 and inserted into a plasmid containing the TBP-N-terminus. The TBP-N-terminal clone containing a polyQ-repeat region expanded from 13- to 50-Q residues was then sub-cloned into TBP-FL, which was inserted into pDsRed2-C1SN for use in co-localization assays.
As controls, three additional cDNAs were inserted into pDSRed2-Cl (MED15) or pDSRed2-C1SN (PTIP and U2AF65). Clones were as follows: amino-acids 429–1056 of the nuclear protein PTIP ; the full-length mouse MED15 open reading frame (ATCC, catalog no. 10699004; NCBI accession number BC054779); and full-length mouse U2AF65 (NCBI accession number BC106134) [46, 47], which was isolated by RT-PCR and subsequent PCR amplification of mouse C57Bl/6J cDNA with primers U2AF-N-start and U2AF-C-end (Table 1).
A GFP-tagged HAP1 protein was constructed by PCR amplification of EGFP with primers GFP-N-start and GFP-C-end (Table 1). The EGFP PCR product was digested with Sal I and inserted into the Sal I site upstream of HAP1-A7–598 in the pCMV-MYC plasmid. This resultant construct was termed pCMV-MYC-GFP-HAP1-A7–598. A red fluorescent protein- (RFP-) tagged HAP1 protein was also constructed by insertion of HAP1-B155–582 into the Sal I site in pDSRed2-C1.
Cell transfection conditions for 293, COS-7, and Neuro-2a cells were similar to those performed for co-immunoprecipitation assays except that 0.5 μg of each plasmid was used for each transfection. In single plasmid transfections, total DNA was brought to 1 μg with pBluescript II KS+ plasmid (Stratagene). Forty-eight hours after transfection, cells were stained with Hoechst 33342 (Sigma) at 1.0 μg/ml in PBS for 15 min, rinsed once, given fresh complete medium, and photographed on a Nikon Eclipse TE300 inverted fluorescent microscope.
Quantitation of relative nuclear and extranuclear TBP
COS-7 cells were transfected as above with the fluorescent fusion proteins indicated in figure legend. Forty-eight hours after transfection, cells were stained with Hoechst and digital fluorescent photomicrographs of cells expressing both HAP1 and TBP were taken (ten or more co-expressing cells per experimental condition were chosen arbitrarily). Hoechst and GFP-HAP1 fluorescence were used to delineate nuclear and cytoplasmic regions, as indicated by white dotted lines in Fig 8A. Because adherent cells have little cytoplasm over- or under-lying the nucleus, most cells gave clear spatial separation of GFP-HAP1 STLB fluorescence and nuclear Hoechst fluorescence; however, a few cells did have evidence of STLBs over- or under-lying the nucleus, and these were excluded from the analysis.
Digital photomicrographs of individual cells were used to estimate relative nuclear and extranuclear TBP levels. Total area, nuclear area, and extranuclear area were analyzed using the "Image Histogram" tool for the red (DSRed2-TBP expression) channel within Photoshop 7.0 (Adobe). The pixel-count per intensity level curve was integrated to provide a quantitative estimate of the total amount of red fluorescence in each compartment. Because this integration takes into account the fluorescence intensity in each pixel, it converts the two-dimensional fluorescent photomicrograph into a quantitative representation of all fluorescence in the three-dimensional space within each cellular region, and thus provides an estimate of relative fluorescent protein concentrations.
Supported by a research grant (0090884) and CAREER Award (0446536) from the National Science Foundation, an NIH/NIAID grant (R01 AI55739-01), a Basil O'Connor New Investigator Award (#5-FY00-520) and a research grant (#6-FY03-61) from the March of Dimes Foundation, and an appointment from the Montana Agricultural Experiment Station to EES. The authors thank A. Siders, O. Lucas, and R. Bessen for assistance or reagents.
- Everett CM, Wood NW: Trinucleotide repeats and neurodegenerative disease. Brain 2004,127(Pt 11):2385-2405. 10.1093/brain/awh278View ArticlePubMedGoogle Scholar
- MacDonald ME, Ambrose CM, Duyao MP, Myers RH, Lin C, Srinidhi L, Barnes G, Taylor SA, James M, Groot N, MacFarlane H, Jenkins B, Anderson MA, Wexler NS, Gusella JF, Bates GP, Baxendale S, Hummerich H, Kirby S, North M, Youngman S, Mott R, Zehetner G, Sedlacek Z, Poustka A, Frischauf A-M, Lehrach H, Buckler AJ, Church D, Doucette-Stamm L, et al.: A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993,72(6):971-983. 10.1016/0092-8674(93)90585-EView ArticleGoogle Scholar
- Landles C, Bates GP: Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series. EMBO Rep 2004,5(10):958-963. 10.1038/sj.embor.7400250PubMed CentralView ArticlePubMedGoogle Scholar
- Li SH, Hosseini SH, Gutekunst CA, Hersch SM, Ferrante RJ, Li XJ: A human HAP1 homologue. Cloning, expression, and interaction with huntingtin. J Biol Chem 1998,273(30):19220-19227. 10.1074/jbc.273.30.19220View ArticlePubMedGoogle Scholar
- Li XJ, Li SH, Sharp AH, Nucifora FC Jr, Schilling G, Lanahan A, Worley P, Snyder SH, Ross CA: A huntingtin-associated protein enriched in brain with implications for pathology. Nature 1995,378(6555):398-402. 10.1038/378398a0View ArticlePubMedGoogle Scholar
- van Roon-Mom WM, Reid SJ, Faull RL, Snell RG: TATA-binding protein in neurodegenerative disease. Neuroscience 2005,133(4):863-872. 10.1016/j.neuroscience.2005.03.024View ArticlePubMedGoogle Scholar
- Koide R, Ikeuchi T, Onodera O, Tanaka H, Igarashi S, Endo K, Takahashi H, Kondo R, Ishikawa A, Hayashi T, Saito M, Tomoda A, Miike T, Naito H, Ikuta F, Tsuji S: Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). Nat Genet 1994,6(1):9-13. 10.1038/ng0194-9View ArticlePubMedGoogle Scholar
- Nagafuchi S, Yanagisawa H, Sato K, Shirayama T, Ohsaki E, Bundo M, Takeda T, Tadokoro K, Kondo I, Murayama N, Tanaka Y, Kikushima H, Umino K, Kurosawa H, Furukawa T, Nihei K, Inoue T, Sano A, Komure O, Takahashi M, Yoshizawa T, Kanazawa I, Yamada M: Dentatorubral and pallidoluysian atrophy expansion of an unstable CAG trinucleotide on chromosome 12p. Nat Genet 1994,6(1):14-18. 10.1038/ng0194-14View ArticlePubMedGoogle Scholar
- La Spada AR, Roling DB, Harding AE, Warner CL, Spiegel R, Hausmanowa-Petrusewicz I, Yee WC, Fischbeck KH: Meiotic stability and genotype-phenotype correlation of the trinucleotide repeat in X-linked spinal and bulbar muscular atrophy. Nat Genet 1992,2(4):301-304. 10.1038/ng1292-301View ArticlePubMedGoogle Scholar
- Li M, Miwa S, Kobayashi Y, Merry DE, Yamamoto M, Tanaka F, Doyu M, Hashizume Y, Fischbeck KH, Sobue G: Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy. Ann Neurol 1998,44(2):249-254. 10.1002/ana.410440216View ArticlePubMedGoogle Scholar
- Beitel LK, Scanlon T, Gottlieb B, Trifiro MA: Progress in Spinobulbar muscular atrophy research: insights into neuronal dysfunction caused by the polyglutamineexpanded androgen receptor. Neurotox Res 2005,7(3):219-230.View ArticlePubMedGoogle Scholar
- Walling HW, Baldassare JJ, Westfall TC: Molecular aspects of Huntington's disease. J Neurosci Res 1998,54(3):301-308. 10.1002/(SICI)1097-4547(19981101)54:3<301::AID-JNR1>3.0.CO;2-WView ArticlePubMedGoogle Scholar
- Saudou F, Finkbeiner S, Devys D, Greenberg ME: Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998,95(1):55-66. 10.1016/S0092-8674(00)81782-1View ArticlePubMedGoogle Scholar
- Schaffar G, Breuer P, Boteva R, Behrends C, Tzvetkov N, Strippel N, Sakahira H, Siegers K, Hayer-Hartl M, Hartl FU: Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol Cell 2004,15(1):95-105. 10.1016/j.molcel.2004.06.029View ArticlePubMedGoogle Scholar
- Ciechanover A, Brundin P: The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 2003,40(2):427-446. 10.1016/S0896-6273(03)00606-8View ArticlePubMedGoogle Scholar
- Sakahira H, Breuer P, Hayer-Hartl MK, Hartl FU: Molecular chaperones as modulators of polyglutamine protein aggregation and toxicity. Proc Natl Acad Sci USA 2002,99(Suppl 4):16412-16418. 10.1073/pnas.182426899PubMed CentralView ArticlePubMedGoogle Scholar
- McCampbell A, Taylor JP, Taye AA, Robitschek J, Li M, Walcott J, Merry D, Chai Y, Paulson H, Sobue G, Fischbeck KH: CREB-binding protein sequestration by expanded polyglutamine. Hum Mol Genet 2000,9(14):2197-2202. 10.1093/hmg/9.14.2197View ArticlePubMedGoogle Scholar
- Perez MK, Paulson HL, Pendse SJ, Saionz SJ, Bonini NM, Pittman RN: Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation. J Cell Biol 1998,143(6):1457-1470. 10.1083/jcb.143.6.1457PubMed CentralView ArticlePubMedGoogle Scholar
- Hernandez N: TBP, a universal eukaryotic transcription factor? Genes Dev 1993,7(7B):1291-1308. 10.1101/gad.7.7b.1291View ArticlePubMedGoogle Scholar
- Nakamura K, Jeong SY, Uchihara T, Anno M, Nagashima K, Nagashima T, Ikeda S, Tsuji S, Kanazawa I: SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum Mol Genet 2001,10(14):1441-1448. 10.1093/hmg/10.14.1441View ArticlePubMedGoogle Scholar
- Schmidt EE, Schibler U: High accumulation of components of the RNA polymerase II transcription machinery in rodent spermatids. Development 1995,121(8):2373-2383.PubMedGoogle Scholar
- Schmidt EE, Schibler U: Cell size regulation, a mechanism that controls cellular RNA accumulation: consequences on regulation of the ubiquitous transcription factors Oct1 and NF-Y and the liver-enriched transcription factor DBP. J Cell Biol 1995,128(4):467-483. 10.1083/jcb.128.4.467View ArticlePubMedGoogle Scholar
- Toyoshima Y, Yamada M, Onodera O, Shimohata M, Inenaga C, Fujita N, Morita M, Tsuji S, Takahashi H: SCA17 homozygote showing Huntington's disease-like phenotype. Ann Neurol 2004,55(2):281-286. 10.1002/ana.10824View ArticlePubMedGoogle Scholar
- Li SH, Yu ZX, Li CL, Nguyen HP, Zhou YX, Deng C, Li XJ: Lack of huntingtinassociated protein-1 causes neuronal death resembling hypothalamic degeneration in Huntington's disease. J Neurosci 2003,23(17):6956-6964.PubMedGoogle Scholar
- Fujinaga R, Kawano J, Matsuzaki Y, Kamei K, Yanai A, Sheng Z, Tanaka M, Nakahama K, Nagano M, Shinoda K: Neuroanatomical distribution of Huntingtin-associated protein 1-mRNA in the male mouse brain. J Comp Neurol 2004,478(1):88-109. 10.1002/cne.20277View ArticlePubMedGoogle Scholar
- Zucker B, Luthi-Carter R, Kama JA, Dunah AW, Stern EA, Fox JH, Standaert DG, Young AB, Augood SJ: Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1. Hum Mol Genet 2005,14(2):179-189. 10.1093/hmg/ddi014View ArticlePubMedGoogle Scholar
- Takeshita Y, Fujinaga R, Zhao C, Yanai A, Shinoda K: Huntingtin-associated protein 1 (HAP1) interacts with androgen receptor (AR) and suppresses SBMA-mutant-ARinduced apoptosis. Hum Mol Genet 2006,15(15):2298-2312. 10.1093/hmg/ddl156View ArticlePubMedGoogle Scholar
- Li XJ, Sharp AH, Li SH, Dawson TM, Snyder SH, Ross CA: Huntingtin-associated protein (HAP1): discrete neuronal localizations in the brain resemble those of neuronal nitric oxide synthase. Proc Natl Acad Sci USA 1996,93(10):4839-4844. 10.1073/pnas.93.10.4839PubMed CentralView ArticlePubMedGoogle Scholar
- Page KJ, Potter L, Aronni S, Everitt BJ, Dunnett SB: The expression of Huntingtinassociated protein (HAP1) mRNA in developing, adult and ageing rat CNS: implications for Huntington's disease neuropathology. Eur J Neurosci 1998,10(5):1835-1845. 10.1046/j.1460-9568.1998.00185.xView ArticlePubMedGoogle Scholar
- Bertaux F, Sharp AH, Ross CA, Lehrach H, Bates GP, Wanker E: HAP1-huntingtin interactions do not contribute to the molecular pathology in Huntington's disease transgenic mice. FEBS Lett 1998,426(2):229-232. 10.1016/S0014-5793(98)00352-4View ArticlePubMedGoogle Scholar
- Nasir J, Duan K, Nichol K, Engelender S, Ashworth R, Colomer V, Thomas S, Disteche CM, Hayden MR, Ross CA: Gene structure and map location of the murine homolog of the Huntington-associated protein, Hap1. Mamm Genome 1998,9(7):565-570. 10.1007/s003359900819View ArticlePubMedGoogle Scholar
- Martin EJ, Kim M, Velier J, Sapp E, Lee HS, Laforet G, Won L, Chase K, Bhide PG, Heller A, Aronin N, Difiglia M: Analysis of Huntingtin-associated protein 1 in mouse brain and immortalized striatal neurons. J Comp Neurol 1999,403(4):421-430. 10.1002/(SICI)1096-9861(19990125)403:4<421::AID-CNE1>3.0.CO;2-5View ArticlePubMedGoogle Scholar
- Li Y, Chin LS, Levey AI, Li L: Huntingtin-associated protein 1 interacts with hepatocyte growth factor-regulated tyrosine kinase substrate and functions in endosomal trafficking. J Biol Chem 2002,277(31):28212-28221. 10.1074/jbc.M111612200View ArticlePubMedGoogle Scholar
- Gutekunst CA, Li SH, Yi H, Ferrante RJ, Li XJ, Hersch SM: The cellular and subcellular localization of huntingtin-associated protein 1 (HAP1): comparison with huntingtin in rat and human. J Neurosci 1998,18(19):7674-7686.PubMedGoogle Scholar
- Shinoda K, Nagano M, Osawa Y: An aromatase-associated cytoplasmic inclusion, the "stigmoid body," in the rat brain: II. Ultrastructure (with a review of its history and nomenclature). J Comp Neurol 1993,329(1):1-19. 10.1002/cne.903290102View ArticlePubMedGoogle Scholar
- Li SH, Gutekunst CA, Hersch SM, Li XJ: Association of HAP1 isoforms with a unique cytoplasmic structure. J Neurochem 1998,71(5):2178-2185.View ArticlePubMedGoogle Scholar
- Shen Y, Kassavetis GA, Bryant GO, Berk AJ: Polymerase (Pol) III TATA box-binding protein (TBP)-associated factor Brf binds to a surface on TBP also required for activated Pol II transcription. Mol Cell Biol 1998,18(3):1692-1700.PubMed CentralView ArticlePubMedGoogle Scholar
- Hertel KJ, Maniatis T: Serine-arginine (SR)-rich splicing factors have an exonindependent function in pre-mRNA splicing. Proc Natl Acad Sci USA 1999,96(6):2651-2655. 10.1073/pnas.96.6.2651PubMed CentralView ArticlePubMedGoogle Scholar
- Canaves JM, Taylor SS: Classification and phylogenetic analysis of the cAMPdependent protein kinase regulatory subunit family. J Mol Evol 2002,54(1):17-29. 10.1007/s00239-001-0013-1View ArticlePubMedGoogle Scholar
- Hori R, Carey M: Transcription: TRF walks the walk but can it talk the talk? Curr Biol 1998,8(4):R124-127. 10.1016/S0960-9822(98)70987-XView ArticlePubMedGoogle Scholar
- Persengiev SP, Zhu X, Dixit BL, Maston GA, Kittler EL, Green MR: TRF3, a TATAbox-binding protein-related factor, is vertebrate-specific and widely expressed. Proc Natl Acad Sci USA 2003,100(25):14887-14891. 10.1073/pnas.2036440100PubMed CentralView ArticlePubMedGoogle Scholar
- Li XJ, Li SH: HAP1 and intracellular trafficking. Trends Pharmacol Sci 2005,26(1):1-3. 10.1016/j.tips.2004.11.001View ArticlePubMedGoogle Scholar
- Berti L, Mittler G, Przemeck GK, Stelzer G, Gunzler B, Amati F, Conti E, Dallapiccola B, Hrabe de Angelis M, Novelli G, Meisterernst M: Isolation and characterization of a novel gene from the DiGeorge chromosomal region that encodes for a mediator subunit. Genomics 2001,74(3):320-332. 10.1006/geno.2001.6566View ArticlePubMedGoogle Scholar
- Thomas MC, Chiang CM: The general transcription machinery and general cofactors. Crit Rev Biochem Mol Biol 2006,41(3):105-178. 10.1080/10409230600648736View ArticlePubMedGoogle Scholar
- Lechner MS, Levitan I, Dressler GR: PTIP, a novel BRCT domain-containing protein interacts with Pax2 and is associated with active chromatin. Nucleic Acids Res 2000,28(14):2741-2751. 10.1093/nar/28.14.2741PubMed CentralView ArticlePubMedGoogle Scholar
- Sailer A, MacDonald NJ, Weissmann C: Cloning and sequencing of the murine homologue of the human splicing factor U2AF65. Nucleic Acids Res 1992,20(9):2374. 10.1093/nar/20.9.2374PubMed CentralView ArticlePubMedGoogle Scholar
- Zhang M, Zamore PD, Carmo-Fonseca M, Lamond AI, Green MR: Cloning and intracellular localization of the U2 small nuclear ribonucleoprotein auxiliary factor small subunit. Proc Natl Acad Sci USA 1992,89(18):8769-8773. 10.1073/pnas.89.18.8769PubMed CentralView ArticlePubMedGoogle Scholar
- Li SH, Li H, Torre ER, Li XJ: Expression of huntingtin-associated protein-1 in neuronal cells implicates a role in neuritic growth. Mol Cell Neurosci 2000,16(2):168-183. 10.1006/mcne.2000.0858View ArticlePubMedGoogle Scholar
- van Roon-Mom WM, Reid SJ, Jones AL, MacDonald ME, Faull RL, Snell RG: Insoluble TATA-binding protein accumulation in Huntington's disease cortex. Brain Res Mol Brain Res 2002,109(1–2):1-10. 10.1016/S0169-328X(02)00450-3View ArticlePubMedGoogle Scholar
- Bondareva AA, Schmidt EE: Early vertebrate evolution of the TATA-binding protein, TBP. Mol Biol Evol 2003,20(11):1932-1939. 10.1093/molbev/msg205PubMed CentralView ArticlePubMedGoogle Scholar
- Schmidt EE, Davies CJ: The origins of polypeptide domains. Bioessays 2007,29(3):262-270. 10.1002/bies.20546PubMed CentralView ArticlePubMedGoogle Scholar
- Sumita K, Makino Y, Katoh K, Kishimoto T, Muramatsu M, Mikoshiba K, Tamura T: Structure of a mammalian TBP (TATA-binding protein) gene: isolation of the mouse TBP genome. Nucleic Acids Res 1993,21(11):2769. 10.1093/nar/21.11.2769PubMed CentralView ArticlePubMedGoogle Scholar
- Li SH, Li XJ: Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet 2004,20(3):146-154. 10.1016/j.tig.2004.01.008View ArticlePubMedGoogle Scholar
- Li SH, Gutekunst CA, Hersch SM, Li XJ: Interaction of huntingtin-associated protein with dynactin P150Glued. J Neurosci 1998,18(4):1261-1269.PubMedGoogle Scholar
- Colomer V, Engelender S, Sharp AH, Duan K, Cooper JK, Lanahan A, Lyford G, Worley P, Ross CA: Huntingtin-associated protein 1 (HAP1) binds to a Trio-like polypeptide, with a rac1 guanine nucleotide exchange factor domain. Hum Mol Genet 1997,6(9):1519-1525. 10.1093/hmg/6.9.1519View ArticlePubMedGoogle Scholar
- Kittler JT, Thomas P, Tretter V, Bogdanov YD, Haucke V, Smart TG, Moss SJ: Huntingtin-associated protein 1 regulates inhibitory synaptic transmission by modulating gamma-aminobutyric acid type A receptor membrane trafficking. Proc Natl Acad Sci USA 2004,101(34):12736-12741. 10.1073/pnas.0401860101PubMed CentralView ArticlePubMedGoogle Scholar
- Marcora E, Gowan K, Lee JE: Stimulation of NeuroD activity by huntingtin and huntingtin-associated proteins HAP1 and MLK2. Proc Natl Acad Sci USA 2003,100(16):9578-9583. 10.1073/pnas.1133382100PubMed CentralView ArticlePubMedGoogle Scholar
- Gunther C, von Hadeln K, Muller-Thomsen T, Alberici A, Binetti G, Hock C, Nitsch RM, Stoppe G, Reiss J, Gal A, Finckh U: Possible association of mitochondrial transcription factor A (TFAM) genotype with sporadic Alzheimer disease. Neurosci Lett 2004,369(3):219-223. 10.1016/j.neulet.2004.07.070View ArticlePubMedGoogle Scholar
- Graveland GA, Williams RS, DiFiglia M: Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 1985,227(4688):770-773. 10.1126/science.3155875View ArticlePubMedGoogle Scholar
- Ohbayashi T, Schmidt EE, Makino Y, Kishimoto T, Nabeshima Y, Muramatsu M, Tamura T: Promoter structure of the mouse TATA-binding protein (TBP) gene. Biochem Biophys Res Commun 1996,225(1):275-280. 10.1006/bbrc.1996.1166View ArticlePubMedGoogle Scholar
- Prigge JR, Schmidt EE: Interaction of protein inhibitor of activated STAT (PIAS) proteins with the TATA-binding protein, TBP. J Biol Chem 2006,281(18):12260-12269. 10.1074/jbc.M510835200PubMed CentralView ArticlePubMedGoogle Scholar
- Gietz RD, Schiestl RH, Willems AR, Woods RA: Studies on the transformation of intact yeast cells by the LiAc/SS-DNA/PEG procedure. Yeast 1995,11(4):355-360. 10.1002/yea.320110408View ArticlePubMedGoogle Scholar
- Hoffman CS, Winston F: A ten-minute DNA preparation from yeast efficiently releases autonomous plasmids for transformation of Escherichia coli. Gene 1987,57(2–3):267-272. 10.1016/0378-1119(87)90131-4View ArticlePubMedGoogle Scholar